Cipla eyes rebound in ‘One India’ business despite slow seasonal growth 0 05.11.2024 13:10 Thehindubusinessline.com Despite facing supply issues with its generic Lanreotide in the US, Cipla anticipates a recovery in sales starting from Q4 FY25. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
